An Evaluation of Duplicate Adverse Event Reports Characteristics in the Food and Drug Administration Adverse Event Reporting System.

IF 4 2区 医学 Q1 PHARMACOLOGY & PHARMACY
Scott Janiczak, Sarah Tanveer, Karen Tom, Rongmei Zhang, Yong Ma, Lisa Wolf, Monica A Muñoz
{"title":"An Evaluation of Duplicate Adverse Event Reports Characteristics in the Food and Drug Administration Adverse Event Reporting System.","authors":"Scott Janiczak, Sarah Tanveer, Karen Tom, Rongmei Zhang, Yong Ma, Lisa Wolf, Monica A Muñoz","doi":"10.1007/s40264-025-01560-7","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>The Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) receives duplicate reports of adverse events associated with drug and therapeutic biological products. Duplicate reports, defined as multiple reports of the same adverse event(s) related to the administration of the same marketed product(s) to the same individual patient at a particular point in time, may be received in FAERS for many reasons. The presence of duplicate reports can negatively impact public health surveillance efforts by impeding both safety signal identification and signal evaluation.</p><p><strong>Objectives: </strong>To characterize the features and contributing factors associated with duplicate reports in FAERS.</p><p><strong>Methods: </strong>We manually assessed a convenience sample of individual case safety reports (ICSRs) for duplication, resulting in two data sets: one consisting of non-duplicate reports and one with duplicate reports. We then compared key features of these two datasets, including both structured and unstructured data fields. Key comparison features included: report and reporter type, country of report origin, data source for report, and outcome. In addition, we evaluated information similarity of reports for seven data elements (e.g., age, sex, suspect products) within sets of duplicates using both structured and unstructured fields. We used pairwise sentence bidirectional encoder representations from transformers (SBERT) cosine similarity scores to examine free-text narrative similarity.</p><p><strong>Results: </strong>Among the 2297 reports in the sample, 272 (12%) were classified as duplicates, consisting of 85 unique duplicate sets. Compared with non-duplicate reports, duplicates were more likely to be foreign reports (85% versus 51%), reported by healthcare professionals (89% versus 74%), mention other regulatory authority databases (44% versus 20%), or describe published case reports (28% versus 19%) (p = 0.01). Within sets of duplicates (n = 85), coded information was frequently different, with only 16% (n = 14) having concordance of all 7 data elements. The narrative was highly similar among most sets of duplicates; we found that the median similarity score for the duplicate pairs was 0.74 compared with 0.38 for non-duplicate pairs.</p><p><strong>Conclusions: </strong>We observed differences in the attributes of and potential contributors to duplicate reports in FAERS that may inform duplicate prevention, detection, and management strategies. However, further studies are needed to better understand the implications of these findings and how potential regulatory changes and technological advances can be leveraged to further address duplicate reporting in adverse event reporting systems.</p>","PeriodicalId":11382,"journal":{"name":"Drug Safety","volume":" ","pages":""},"PeriodicalIF":4.0000,"publicationDate":"2025-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug Safety","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s40264-025-01560-7","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: The Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) receives duplicate reports of adverse events associated with drug and therapeutic biological products. Duplicate reports, defined as multiple reports of the same adverse event(s) related to the administration of the same marketed product(s) to the same individual patient at a particular point in time, may be received in FAERS for many reasons. The presence of duplicate reports can negatively impact public health surveillance efforts by impeding both safety signal identification and signal evaluation.

Objectives: To characterize the features and contributing factors associated with duplicate reports in FAERS.

Methods: We manually assessed a convenience sample of individual case safety reports (ICSRs) for duplication, resulting in two data sets: one consisting of non-duplicate reports and one with duplicate reports. We then compared key features of these two datasets, including both structured and unstructured data fields. Key comparison features included: report and reporter type, country of report origin, data source for report, and outcome. In addition, we evaluated information similarity of reports for seven data elements (e.g., age, sex, suspect products) within sets of duplicates using both structured and unstructured fields. We used pairwise sentence bidirectional encoder representations from transformers (SBERT) cosine similarity scores to examine free-text narrative similarity.

Results: Among the 2297 reports in the sample, 272 (12%) were classified as duplicates, consisting of 85 unique duplicate sets. Compared with non-duplicate reports, duplicates were more likely to be foreign reports (85% versus 51%), reported by healthcare professionals (89% versus 74%), mention other regulatory authority databases (44% versus 20%), or describe published case reports (28% versus 19%) (p = 0.01). Within sets of duplicates (n = 85), coded information was frequently different, with only 16% (n = 14) having concordance of all 7 data elements. The narrative was highly similar among most sets of duplicates; we found that the median similarity score for the duplicate pairs was 0.74 compared with 0.38 for non-duplicate pairs.

Conclusions: We observed differences in the attributes of and potential contributors to duplicate reports in FAERS that may inform duplicate prevention, detection, and management strategies. However, further studies are needed to better understand the implications of these findings and how potential regulatory changes and technological advances can be leveraged to further address duplicate reporting in adverse event reporting systems.

食品药品监督管理局不良事件报告系统中重复不良事件报告特征的评价。
美国食品和药物管理局(FDA)不良事件报告系统(FAERS)收到与药物和治疗性生物制品相关的不良事件的重复报告。由于多种原因,FAERS可能会收到重复报告,重复报告定义为同一患者在特定时间点服用同一上市产品时发生的相同不良事件的多个报告。重复报告的存在会阻碍安全信号识别和信号评估,从而对公共卫生监测工作产生负面影响。目的:描述FAERS中重复报告的特征和影响因素。方法:我们手动评估了一个方便样本的个案安全报告(ICSRs)的重复,产生两个数据集:一个由非重复报告组成,另一个有重复报告。然后,我们比较了这两个数据集的关键特征,包括结构化和非结构化数据字段。主要的比较特征包括:报告和报告者类型、报告原产国、报告数据来源和结果。此外,我们使用结构化和非结构化字段评估了重复集中七个数据元素(例如,年龄、性别、可疑产品)报告的信息相似性。我们使用来自变形金刚(SBERT)余弦相似度分数的两两句子双向编码器表示来检查自由文本叙事相似度。结果:在样本的2297份报告中,有272份(12%)被归类为重复,由85个独特的重复集组成。与非重复报告相比,重复报告更有可能是外国报告(85%对51%)、由医疗保健专业人员报告(89%对74%)、提到其他监管机构数据库(44%对20%)或描述已发表的病例报告(28%对19%)(p = 0.01)。在重复集(n = 85)中,编码信息经常不同,只有16% (n = 14)的所有7个数据元素具有一致性。大多数副本的叙述都非常相似;我们发现重复对的中位数相似性得分为0.74,而非重复对的中位数相似性得分为0.38。结论:我们观察到FAERS中重复报告的属性和潜在因素的差异,这可能为重复预防、检测和管理策略提供信息。然而,需要进一步的研究来更好地理解这些发现的含义,以及如何利用潜在的监管变化和技术进步来进一步解决不良事件报告系统中的重复报告问题。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Drug Safety
Drug Safety 医学-毒理学
CiteScore
7.60
自引率
7.10%
发文量
112
审稿时长
6-12 weeks
期刊介绍: Drug Safety is the official journal of the International Society of Pharmacovigilance. The journal includes: Overviews of contentious or emerging issues. Comprehensive narrative reviews that provide an authoritative source of information on epidemiology, clinical features, prevention and management of adverse effects of individual drugs and drug classes. In-depth benefit-risk assessment of adverse effect and efficacy data for a drug in a defined therapeutic area. Systematic reviews (with or without meta-analyses) that collate empirical evidence to answer a specific research question, using explicit, systematic methods as outlined by the PRISMA statement. Original research articles reporting the results of well-designed studies in disciplines such as pharmacoepidemiology, pharmacovigilance, pharmacology and toxicology, and pharmacogenomics. Editorials and commentaries on topical issues. Additional digital features (including animated abstracts, video abstracts, slide decks, audio slides, instructional videos, infographics, podcasts and animations) can be published with articles; these are designed to increase the visibility, readership and educational value of the journal’s content. In addition, articles published in Drug Safety Drugs may be accompanied by plain language summaries to assist readers who have some knowledge of, but not in-depth expertise in, the area to understand important medical advances.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信